EMA accepts Pfizer-Valneva Lyme disease vaccine for review
The European Medicines Agency has accepted for formal review a marketing authorisation application for a Lyme disease vaccine developed by Pfizer and Valneva — a step that, if it ends in approval, would produce the first licensed Lyme vaccine for humans. Valneva shares closed